Benltifa, M., Hayes, Joseph ORCID: 0000-0002-7745-9616, Vidal, S., Gueyrard, D., Goekjian, P.G., Praly, J.-P., Kizilis, G., Tiraidis, C., Alexacou, K.-M. et al (2009) Glucose-based spiro-isoxazolines: A new family of potent glycogen phosphorylase inhibitors. Bioorganic and Medicinal Chemistry, 17 (20). pp. 7368-7380. ISSN 09680896
PDF (Publisher's post-print for classroom teaching and internal training purposes at UCLan)
- Published Version
Restricted to Registered users only 1MB |
Official URL: http://dx.doi.org/10.1016/j.bmc.2009.08.060
Abstract
A series of glucopyranosylidene-spiro-isoxazolines was prepared through regio- and stereoselective 3+2-cycloaddition between the methylene acetylated exo-glucal and aromatic nitrile oxides. The deprotected cycloadducts were evaluated as inhibitors of muscle glycogen phosphorylase b. The carbohydrate-based family of five inhibitors displays Ki values ranging from 0.63 to 92.5 μM. The X-ray structures of the enzyme-ligand complexes show that the inhibitors bind preferentially at the catalytic site of the enzyme retaining the less active T-state conformation. Docking calculations with GLIDE in extra-precision (XP) mode yielded excellent agreement with experiment, as judged by comparison of the predicted binding modes of the five ligands with the crystallographic conformations and the good correlation between the docking scores and the experimental free binding energies. Use of docking constraints on the well-defined positions of the glucopyranose moiety in the catalytic site and redocking of GLIDE-XP poses using electrostatic potential fit-determined ligand partial charges in quantum polarized ligand docking (QPLD) produced the best results in this regard.
Repository Staff Only: item control page